CALGENT BIOTECHNOLOGY CO.

Led by Dr. Yun Yen, the team aims for a first-in-class, low toxicity oral anti-cancer drug namely MPT0L056, an ITCH E3 ubiquitin ligase inhibitor which is to be marketed for treating multiple myeloma and pancreatic cancer. MPT0L056 features include: 1. High cytotoxic activity and selectivity against cancer cells. MPT0L056 selectively inhibits the growth of cancer cells, presenting a broader therapeutic window. 2. Specific inhibition toward ITCH E3 ubiquitin ligase activity. Compared with other commercially available ubiquitin proteasome pathway (UPP) inhibitors, for example Bortezomib, MPT0L056 causes fewer side effects. 3. A good oral bioavailability. MPT0L056 is an oral anti-cancer drug.